×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BHVN – biohaven ltd. common shares (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BHVN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
09:23 am
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
12/17
08:15 am
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
Medium
Report
Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
12/16
07:47 am
bhvn
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates [Yahoo! Finance]
Medium
Report
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates [Yahoo! Finance]
12/16
07:30 am
bhvn
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates
Medium
Report
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates
12/6
07:34 am
bhvn
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting [Yahoo! Finance]
12/6
07:30 am
bhvn
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting
Medium
Report
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting
12/4
12:27 pm
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $61.00 price target on the stock, up previously from $58.00.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $61.00 price target on the stock, up previously from $58.00.
11/29
07:00 am
bhvn
Biohaven's Revenue Path: SCA And Obesity Therapies [Seeking Alpha]
Low
Report
Biohaven's Revenue Path: SCA And Obesity Therapies [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
04:05 pm
bhvn
biohaven ltd. common shares
MISS
Report
-2.6%
biohaven ltd. common shares
8/8/2024
04:05 pm
bhvn
biohaven ltd. common shares
MISS
Report
6.3%
biohaven ltd. common shares
5/9/2024
04:05 pm
bhvn
biohaven ltd. common shares
MISS
Report
-13.7%
biohaven ltd. common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
03:07 pm
bhvn
Form SC 13G/A Biohaven Ltd. Filed by: JANUS HENDERSON GROUP PLC
Low
Report
Form SC 13G/A Biohaven Ltd. Filed by: JANUS HENDERSON GROUP PLC
11/12
04:17 pm
bhvn
Form 8-K Biohaven Ltd. For: Nov 12
Medium
Report
Form 8-K Biohaven Ltd. For: Nov 12
11/12
04:13 pm
bhvn
Form 10-Q Biohaven Ltd. For: Sep 30
Low
Report
Form 10-Q Biohaven Ltd. For: Sep 30
11/12
01:20 pm
bhvn
Form SC 13G/A Biohaven Ltd. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Biohaven Ltd. Filed by: VANGUARD GROUP INC
11/4
11:17 am
bhvn
Form SC 13G/A Biohaven Ltd. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Biohaven Ltd. Filed by: VANGUARD GROUP INC
10/3
07:01 am
bhvn
Form 4 Biohaven Ltd. For: Oct 02 Filed by: Coric Vlad
Low
Report
Form 4 Biohaven Ltd. For: Oct 02 Filed by: Coric Vlad
10/3
07:01 am
bhvn
Form 4 Biohaven Ltd. For: Oct 02 Filed by: CHILDS JOHN W
Low
Report
Form 4 Biohaven Ltd. For: Oct 02 Filed by: CHILDS JOHN W
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/16
Form DEFA14A Biohaven Pharmaceutical
14.2%
2/10 Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List 12.9%
7/22 Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled 10.4%
9/4 Form 8-K Biohaven Pharmaceutical For: Sep 04 9.3%
2/27 Biohaven's NURTEC™ ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults 8.1%
7/15 Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet 7.6%
3/12 Form 5 Biohaven Pharmaceutical For: Dec 31 Filed by: Coric Vlad 7.2%
5/7 Form 8-K Biohaven Pharmaceutical For: May 07 6.5%
4/27 Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC™ ODT in the Middle East 5.9%
1/27 Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.7%
2/10 Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List 12.9%
7/22 Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled 10.4%
9/4 Form 8-K Biohaven Pharmaceutical For: Sep 04 9.3%
2/27 Biohaven's NURTEC™ ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults 8.1%
7/15 Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet 7.6%
3/12 Form 5 Biohaven Pharmaceutical For: Dec 31 Filed by: Coric Vlad 7.2%
5/7 Form 8-K Biohaven Pharmaceutical For: May 07 6.5%
4/27 Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC™ ODT in the Middle East 5.9%
1/27 Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.7%
TOP News Decliners
3/31
Form 8-K Biohaven Pharmaceutical For: Mar 30
-13.6%
6/17 Biohaven Announces Proposed Public Offering Of Common Shares -12.4%
1/10 Form 4 Biohaven Pharmaceutical For: Jan 08 Filed by: Stock Elyse -11.2%
12/17 Biohaven Pharma says acute migraine treatment succeeds in study [Reuters] -10.7%
1/28 Biohaven Announces Proposed Public Offering Of Common Shares -8.8%
6/18 Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares -7.2%
12/6 Biohaven Pharma to continue late-stage study of Alzheimer's treatment [Reuters] -7.0%
4/7 Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC™ ODT -5.9%
2/10 Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint -5.9%
3/30 Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine -5.0%
6/17 Biohaven Announces Proposed Public Offering Of Common Shares -12.4%
1/10 Form 4 Biohaven Pharmaceutical For: Jan 08 Filed by: Stock Elyse -11.2%
12/17 Biohaven Pharma says acute migraine treatment succeeds in study [Reuters] -10.7%
1/28 Biohaven Announces Proposed Public Offering Of Common Shares -8.8%
6/18 Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares -7.2%
12/6 Biohaven Pharma to continue late-stage study of Alzheimer's treatment [Reuters] -7.0%
4/7 Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC™ ODT -5.9%
2/10 Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint -5.9%
3/30 Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine -5.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: